Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-23-021911

Chief Executive Officer sold 25,000 shares at an average $44.46 ($1,111,504)

  • Chief Executive Officer acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2023-03-29 Option exercise +25,000 $19.12 $478,000 412,377 D: show line 1 in the form
Kulkarni Samarth Chief Executive Officer 2023-03-29 Sale −19,719 $44.37 $874,997 392,658 D: show line 2 in the form
Kulkarni Samarth Chief Executive Officer 2023-03-29 Sale −5,281 $44.78 $236,506 387,377 D: show line 3 in the form
Open-market sales · 25,000 sh · avg $44.46 · $1,111,504

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Kulkarni Samarth Chief Executive Officer 2023-03-29 Option exercise · Stock Option (Right to Buy) −25,000 129,582 D: show line 4 in the form
Loading xslF345X04/doc4.xml…